Effect of Fenofibrate on Patients with Hyperlipidemic Acute Pancreatitis
Objective:To study the effect of Fenofibrate on patients with hyperlipidemic acute pancreatitis(HAP).Method:A total of 120 HAP patients admitted to Xiangcheng People's Hospital of Suzhou City from July 2020 to June 2023 were selected.According to the order of admission,the patients were randomly divided into control group(53 cases)and observation group(67 cases).The control group received conventional treatment,and the observation group received Fenofibrate on the basis of the control group.Triglyceride(TG)levels,blood lipid indexes,inflammatory factors and related scores before and after treatment were compared between the two groups.Result:On the first day,the second day,the third day,the fourth day,the fifth day of treatment,the TG level of observation group was lower than that of control group,and the difference was statistically significant(P＜0.05).After treatment,the levels of high-density lipoprotein(HDL)were increased,and the levels of low-density lipoprotein(LDL)and total cholesterol(TC)were decreased in both groups,the levels of HDL in the observation group were higher than those in the control group,while the levels of LDL and TC were lower than those in the control group,and the differences were statistically significant(P＜0.05).After treatment,the levels of trypsinogen 2(TPG-2),tumor necrosis factor-α(TNF-α)and interleukin-8(IL-8)in both groups were decreased,and the levels of TPG-2,TNF-α and IL-8 in observation group were lower than those in control group,and the differences were statistically significant(P＜0.05).After treatment,Ranson scores and acute physiology and chronic health assessment Ⅱ(APACHEⅡ)scores in the observation group were lower than those in the control group,and the differences were statistically significant(P＜0.05).Conclusion:Fenofibrate can effectively reduce TG level,lipid level and inflammatory response in HAP patients,and can be used as an effective adjuvant therapy.
国家科技期刊平台
NSTL
万方数据
